Skip to main content

Advertisement

SpringerLink
Log in

Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cisplatin (DDP) has been successfully used in the treatment of gastric cancer; however, resistance of gastric tumors to cisplatin has also resulted in frequent treatment failure. To investigate the effect of sorafenib in reversing the resistance of human gastric cancer cell line SGC7901/DDP to treatment by cisplatin, and to examine possible underlying mechanisms. A SGC7901/DDP cell line was treated with different concentrations of sorafenib, with and without cisplatin. The reversing ability of sorafenib on cisplatin treatment was examined using MTT, FACS, and xenograft models. Western blotting and immunofluorescence were used to determine expressions of MDR1, p-Akt, and p-ERK. Sorafenib inhibited proliferation of human gastric cancer cell line SGC7901/DDP, both when used alone and in combination with cisplatin. Expression levels of MDR1, p-Akt, and p-ERK were significantly decreased after sorafenib treatment. Sorafenib may reverse resistance of human gastric cancer cell line SGC7901/DDP to cisplatin through down-regulating MDR1 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Ramos JW. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int J Biochem Cell Biol. 2008;40(12):2707–19.

    Article  CAS  PubMed  Google Scholar 

  3. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res. 2008;14(2):342–6.

    Article  CAS  PubMed  Google Scholar 

  5. Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, et al. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res. 2010;70:1120–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol. 2008;73:1168–84.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Walker T, Mitchell C, Park MA, Yacoub A, Graf M, Rahmani M, et al. Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol. 2009;76:342–55.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol. 2009;76:327–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther. 2010;9:2220–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.

    Article  PubMed  Google Scholar 

  11. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, Hou T, et al. New use for an old drug:inhibiting ABCG2 with sorafenib. Mol Cancer Ther. 2012;11:1693–702.

    Article  CAS  PubMed  Google Scholar 

  12. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15:6062–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Carloni S, Fabbri F, Brigliadori G, Ulivi P, Silvestrini R, Amadori D, et al. Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells. Curr Cancer Drug Targets. 2010;10:422–31.

    Article  CAS  PubMed  Google Scholar 

  14. Wei L, Huang N, Yang L, Zheng DY, Cui YZ, Li AM, Lü CW, Zheng H, Luo RC. Sorafenib reverses multidrug resistance of hepatoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(5):1016–9, 1023.

  15. Chen XP, Wang Q, Guan J, Huang ZY, Zhang WG, Zhang BX. Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J Gastroenterol. 2006;12(21):3332–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Du Y, Su T, Zhao L, Tan X, Chang W, Zhang H, Cao G. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS One. 2014;9(6):e99843.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Chen J, Ding Z, Peng Y, Pan F, Li J, Zou L, Zhang Y, Liang H. HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein. PLoS One. 2014;9(6):e98882.

    Article  PubMed Central  PubMed  Google Scholar 

  18. He Q, Zhang G, Hou D, et al. Overexpression of sorcin results in multidrug resistance in gastric cancer cells with up-regulation of P-gp. Oncol Rep. 2011;25(1):237–43.

    CAS  PubMed  Google Scholar 

  19. Shi H, Lu D, Shu Y, et al. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest. 2008;26(4):344–51.

    Article  CAS  PubMed  Google Scholar 

  20. Woehlecke H, Pohl A, Alder-Baerens N, et al. Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2). Biochem J. 2003;376(Pt 2):489–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Fan K, Fan D, Cheng LF, et al. Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res. 2000;20(6C):4809–14.

    CAS  PubMed  Google Scholar 

  22. Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012;30(1):306–15.

    Article  CAS  PubMed  Google Scholar 

  23. Sun W, Powell M, O’Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28(18):2947–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29(6):L1449–58.

    Article  Google Scholar 

  25. Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011;47(10):1511–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Grants from Medicine Science Research of Guangdong Province (Nos. A2009036, A2014034) and Science and Technology Projects of Guangdong Province (No. 2012B031800163) and Clinical Medicine Scientific Research Foundation of Wu Jie-ping (No. 320.6700.09043).

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Division 1 of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China

    Yi-sheng Huang

  2. Department of Medical Research, Guangdong General Hospital, Guangdong Lung Cancer Institute, Guangdong Key Laboratory of Lung Cancer Translational Medicine, Guangzhou, China

    Zhi Xue

  3. Department of Medical Oncology, Cancer Center, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China

    Hua Zhang

Authors
  1. Yi-sheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhi Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Zhang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Ys., Xue, Z. & Zhang, H. Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression. Med Oncol 32, 24 (2015). https://doi.org/10.1007/s12032-014-0470-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-014-0470-1

Keywords

Search

Navigation